


### Supplemental Figure S1

Splenocytes from wild-type and calnexin-deficient EAE mice were stimulated *in vitro* with MOG<sub>35–55</sub> peptide.

- A.** CD4<sup>+</sup>/CD3<sup>+</sup> and CD8<sup>+</sup>/CD3<sup>+</sup> T-cell populations were analyzed by flow cytometry  
**B.** MHC I and MHC II population of splenocytes were analyzed by flow cytometry, MFI (mean fluorescence intensity). Data represented as mean ± SEM of three replicates of three independent experiments.  
 The means were compared using unpaired Student's t-test.



**Supplemental Figure S2**


Disruption of the calnexin gene in the bEND.3 cell using *in situ* gene editing.

### Supplemental Table S1


#### Summary of Clinical Data

Sample Type	No. of patients	Males	Females	Age at death		Post Mortem Delay		MS disease duration	
				Mean	Range	Mean	Range	Mean	Range
Controls	10	8	2	66.1	28 - 88	22.8	15 - 33	-	-
MS	18	7	11	53.6	35 - 74	22.5	8 - 56	18.1	2 - 34


MS, Multiple Sclerosis



full unedited gel for Figure 4B



full unedited gel for the Figure 6A liver




full unedited gel for the Figure 7A



full unedited gel for the Figure 7B anti-calnexin (upper gel) + loading control (lower gel)


empty lane removed in the final Figure




full unedited gel for the Figure 7C anti-VCAM + loading control



full unedited gel for the Figure 7C anti-VCAM



full unedited gel for the Figure 7D anti-JAM-A (upper gel) + loading control (lower gel)



full unedited gel for the Figure 7D anti-PECAM